Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Aquadra® -- the Next AIDS Blockbuster

| 7 Comments

GileadOkay, okay, so it's still years away from becoming a reality, and I'm just guessing at its future brand name, but we heard this week that Gilead Sciences is working on a new combo HIV drug that will include four drugs in one pill. Marilyn Chase at Bloomberg was the first to report it, and AIDSmeds did a story on it as well.

Gilead is the current leader in overall sales of AIDS drugs, including Atripla, the three-drug once-a-day pill that they co-market with Bristol-Myers Squibb. But Atripla still has an Achilles’ heel -- the central-nervous system side effects of Sustiva, one of its built-in drugs. Most patients take it with no problem, with some even enjoying the vivid dreams it can cause. But there's a subgroup that has trouble sleeping while taking Sustiva or Atripla. Some have worse side effects, as when the drugs cause depression.

Gilead thinks it can do better, while freeing itself from sharing revenue with BMS (the makers of Sustiva). The next AIDS blockbuster drug is in the works. It would combine the other two drugs from Atripla (tenofovir and emtricitabine, sold in combo as Truvada), with their experimental integrase inhibitor, elvitegravir, plus a fourth experimental drug that AIDS activists have been dreaming about for years -- a new (and better?) booster drug that will break the monopoly currently exploited by Abbott Laboratories with their drug, Norvir.

As most of you probably know, Abbott infuriated AIDS activists (including this one) when it jacked up the price of Norvir by 400 percent once researchers discovered its utility in boosting the pharmacokinetics of protease inhibitors (and now integrase inhibitors). So even though their own PI, Kaletra, includes the Norvir booster built-in (at no extra cost to patients), the company was able to raise the cost of all their competitors' drugs which require the separate Norvir booster, like BMS's Reyataz and GSK's Lexiva.

AIDS activists have tried and are still trying everything in their toolbox to convince Abbott to reverse this gross example of AIDS profiteering, but to no avail. But now our knight on a white horse may arrive soon -- Gilead has discovered a potential new booster drug, called GS-9350, and is already studying it in a phase I trial. If it turns out to have fewer side effects than Norvir (which can cause GI effects and raise blood lipids), and Gilead works with activists on pricing (they've got a good record thus far working with the Fair Pricing Coalition), then we could all say goodbye to our overpriced Norvir.

While Aquadra® is still years away (got a better name? suggest one below), it might eventually surpass Atripla as the biggest selling AIDS drug. Gilead has already indicated that the final pill might be smaller than Atripla's horse-pill size. But its true potential might lie in fewer side effects. Thus far, elvitegravir has shown few if any side effects, unlike Sustiva. If the same holds true for GS-9350 (vs. Norvir), then Aquadra® will become the biggest advance in AIDS treatment since Isentress -- Merck's potent first-in-class integrase inhibitor.

There could be one big downside to all this. If Gilead ends up with an overwhelming share of the AIDS drug market, the other big players (GKS, BMS, Merck, Abbott, Tibotec) might raise white flags and chop or end their own AIDS research programs (or what's left of them).

Definitely something to watch.



Peter on:

7 Comments

Show Comment(s)

Comments on Peter Staley's blog entry "Aquadra® -- the Next AIDS Blockbuster"

Aquadra might have trademark problems with QLT. QLT is a drug research company that's been troubled lately (ever since my mother-in-law bought a big chunk, sigh), but still exists. The company name derives from "Quadra Logic Technologies." This may cause reservations about using "quadra" in new drugs.

I thought aquadra sounds like it might have something to do with water. It's sounds more like a diuretic :)
How about quatrovia?

Hey, here's a thought: how about Gilead PAYING me to come up with a name for their drug?

Atripla is a "horse pill"? It's really no bigger than my vitamins. Back when I took amprenavir, now those were horse pills, and a bunch of 'em to boot.

As for the name, how going the Greek route, like "Tetravir"

Atripla has other quite powerful side effects for some users. I took it for a year, during which time I had some of the worst eczema I have ever experienced: my hands cracked and bled, they swelled, the skin peeled off in sheets, the joints became inflamed, and there were days when I simply sat and cried at my desk job because touching my keyboard was so painful. Switched to reyetaz/truvada and within a week I could use my hands again.

I am also on Reyetaz/Truvada, and when I switched, I only had ONE day of slight discomfort. Now my T-Cells are over 800 and viral load <50 micro liters/mL. Also, my ratio is the highest ever.
I really wish these people who have bad side effects, would work with their doctor to find what is right for them.
Sincerely,
J. Todd DeShong
www.dissidents4dumbees.blogspot.com

I like your old picture better (not that you can take a bad picture).

Leave a comment



Archives

Subscribe to Blog

Powered by MT-Notifier

About this Entry

This page contains a single entry by Peter Staley published on January 15, 2009 11:15 AM.

Restoring CD4s to "Normal" was the previous entry in this blog.

America's Most Influential AIDS Treatment Activist Dies is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Peter on Twitter

Disclaimer

The opinions expressed by the bloggers and by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong and/or its employees.

Smart + Strong is not responsible for the accuracy of any of the information contained in the blogs or within any comments posted to the blogs.



© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy